Raptor Pharmaceutical Corp.  

(Public, NASDAQ:RPTP)   Watch this stock  
Find more results for William M. Daley
11.91
+0.02 (0.17%)
May 21 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.64 - 12.03
52 week 7.82 - 12.23
Open 11.93
Vol / Avg. 0.00/1.16M
Mkt cap 956.91M
P/E     -
Div/yield     -
EPS -0.87
Shares 80.48M
Beta 0.07
Inst. own 53%
Aug 5, 2015
Q2 2015 Raptor Pharmaceutical Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 19, 2015
Raptor Pharmaceutical Corp Annual Shareholders Meeting
May 13, 2015
Raptor Pharmaceutical Corp at Bank of America Merrill Lynch Health Care Conference
May 7, 2015
Q1 2015 Raptor Pharmaceutical Corp Earnings Call
May 7, 2015
Q1 2015 Raptor Pharmaceutical Corp Earnings Release
Apr 30, 2015
Raptor Pharmaceutical Corp Investor Day
Mar 3, 2015
Raptor Pharmaceutical Corp at Cowen Health Care Conference
Feb 26, 2015
Q4 2014 Raptor Pharmaceutical Corp Earnings Call
Feb 26, 2015
Q4 2014 Raptor Pharmaceutical Corp Earnings Release
Feb 23, 2015
Raptor Pharmaceutical Corp at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -96.24% -75.60%
Operating margin -71.68% -57.63%
EBITD margin - -56.14%
Return on average assets -43.61% -35.29%
Return on average equity -190.93% -135.56%
Employees 123 -
CDP Score - -

Address

7 Hamilton Lndg Ste 100
NOVATO, CA 94949-8246
United States - Map
+1-415-4086200 (Phone)
+1-415-3828002 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Raptor Pharmaceutical Corp. is a biopharmaceutical company. The Company is focused on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases. The Company’s product, PROCYSBI (cysteamine bitartrate) delayed-release capsules, received approval from the United States Food and Drug Administration. The Company has active clinical development programs in multiple therapeutic areas such as nephropathic cystinosis, nonalcoholic fatty liver disease, Huntington’s disease (HD), and Leigh syndrome and other mitochondrial disease. The Company’s preclinical programs consist of HepTide and ADO (cysteamine dioxygenase).

Officers and directors

Llew Keltner Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Julie Anne Smith President, Chief Executive Officer Designate, Director
Age: 44
Bio & Compensation  - Reuters
Michael P. Smith Chief Financial Officer
Age: 47
Bio & Compensation  - Reuters
Robert H. Uhl Managing Director
Bio & Compensation  - Reuters
Thomas E Daley Chief Business Officer
Age: 52
Bio & Compensation  - Reuters
David A Happel Chief Commercial Officer
Age: 52
Bio & Compensation  - Reuters
Krishna R. Polu M.D. Chief Medical Officer
Age: 41
Bio & Compensation  - Reuters
Georges Gemayel Ph.D. Director
Age: 54
Bio & Compensation  - Reuters
Gregg A. Lapointe C.P.A. Director
Age: 56
Bio & Compensation  - Reuters
Christopher M. Starr Ph.D. Director
Age: 62
Bio & Compensation  - Reuters